Abstract
Liposomes have been widely used in pulmonary drug delivery for multiple applications including solubilization, sustained release, cellular and intracellular targeting, minimization of toxicity, and facilitation of absorption. In this chapter, formulation aspects, aerosolization, and an extensive overview of the use of pulmonary drug delivery of liposomes for disease and drug classes are provided. Specifically, this chapter examines liposomes from in vitro work to clinical studies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Rawat M, Singh D, Saraf S, Saraf S (2008) Lipid carriers: a versatile vehicle for proteins and peptides. Yakugaku Zasshi 128(2):269–280
Samad A, Sultana Y, Aqil M (2007) Liposomal drug delivery systems: an update review. Curr Drug Deliv 4:297–305
Weiner AL (1994) Liposomes for protein delivery: selecting manufacture and developmental processes. Immunomethods 4:201–209
Guo J, Ping Q, Zhang L (2000) Transdermal delivery of insulin in mice by using lecithin vesicles as carrier. Drug Deliv 7:113–116
Lenk RP, Janoff AS, Ostro MJ (1985) Novel multilayered lipid vesicles: Comparison of physical characteristics of multilamellar liposomes and stable plurilamellar vesicles. Biochemistry 24:2833–2842
Storm G, Crommelin DJA (1998) Liposomes: quo vadis? PSTT 1:19–31
Bangham AD (1972) Model membranes. Chem Phys Lipid 8:386–392
Bangham AD, Standish MM, Watkins JC, Weissmann G (1967) The diffusion of ions from a phospholipid model membrane system. Protoplasma 63:183–187
Immordino ML, Dosio F, Cattel L (2006) Stealth liposomes: review of the basic science, rationale and clinical applications, existing and potential. Int J Nanomed 3:297–315
Seltzer SE (1989) The role of liposomes in diagnostic imaging. Radiology 171:19–21
Rhodes BA (1976) Liposomes and vesicles: a new class of radiopharmaceuticals? J Nucl Med 17:1102–1103
Gaspar MM, Bakowsky U, Ehrhardt C (2008) Inhaled liposomes – current strategies and future challenges. J Biomed Nanotechnol 4:1–13
Geiger K, Gallagher ML, Hedley-White J (1975) Cellular distribution and clearence of aerosolized dipalmitoyl lecithin. J Appl Physiol 39:759–766
Oyarzun MJ, Clements JA, Baritusso A (1980) Ventilation enhances pulmonary alveolar clearance of radioactive dipalmitoyl phosphatidylcholine in liposomes. Am Rev Respir Dis 121:709–721
Oyarzun MJ, Clements J (1977) Ventilatory and cholinergic control of pulmonary surfactant in the rabbit. J Appl Physiol 43:39–45
Pre J, Perret G, Bladier D (1983) Lecithin content estimate of human alveolar lining layer, comparison with mouse, rat and rabbit. Comp Biochem Physiol 76:393–395
Mihalko PJ, Schreier H, Abra RM (1988) Liposomes: a pulmonary perspective. In: Gregoriadis G (ed) Liposomes as drug carriers. Wiley, NewYork, pp 679–694
Goerke J (1998) Pulmonary surfactant: functions and molecular composition. Biochim Biophys Acta 1408:79–89
Juliano RL, McCullough HN (1980) Controlled delivery of an anti-tumor drug, localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system. J Pharmacol Exp Ther 214:381–387
Mizushima Y, Hoshi K, Aihara H, Kurachi M (1983) Inhibition of bronchoconstriction by aerosol of a lipid emulsion containing prostaglandin E1. J Pharm Pharmacol 35:397
Farr SJ, Kellaway IW, Parry-Jones D, Woolfrey SG (1985) The clearance of 99m Tc labelled liposomes from the lungs of volunteers. Proceed Intern Symp Control Rel Bioact Mater 12:219–220
Shek PN, Suntres ZE, Brooks JI (1994) Liposomes in pulmonary applications: physicochemical considerations, pulmonary distribution and antioxidant delivery. J Drug Target 2:431–442
Ulrich AS (2002) Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep 22:129–150
Bridges PA, Taylor KMG (1998) Nebulizers for the generation of liposomal aerosols. Int J Pharm 173:117–125
Zaru M, Mourtas S, Klepetsanis P, Fadda AM, Antimisiaris SG (2007) Liposomes for drug delivery to the lungs by nebulisation. Eur J Pharm Biopharm 67:655–666
Bi R, Shao W, Wang Q, Zhang N (2008) Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J Drug Target 16:639–648
Shahiwala A, Misra A (2004) Pulmonary absorption of liposomal levonorgesterol. AAPS PharmSciTech 5:1–5
Desai TR, Wong JP, Hancock REW, Finlay WH (2002) A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling. J Pharm Sci 91:482–491
Steckel H, Eskandar F (2003) Factors affecting aerosol performance during nebulisation with jet and ultrasonic nebulisers. Eur J Pharm Sci 19:443–455
Bridges PA, Taylor KMG (2000) An investigation of some of the factors influencing the jet nebulisation of liposomes. Int J Pharm 204:69–79
Elhissi AMA, Faizi M, Naji WF, Gill HS, And Taylor KMG (2007) Physical stability and aerosol properties of liposomes delivered using an air-jet nebuliser and a novel micropump device with large mesh apertures. Int J Pharm 334:62–70
Leung KKM, Bridges PA, Taylor KMG (1996) The stability of liposomes to ultrasonic nebulisation. Int J Pharm 145:95–102
Gaspar MM, Gobbo O, Ehrhardt C (2009) Generation of liposome aerosols with the Aeroneb Pro and the AeroProbe nebulisers. J Liposome Res. doi: DOI: 10.1080/08982100903085150
Rau JL, Ari A, Restrepo RD (2004) Performance comparison of nebuliser designs: constant-output, breath-enhanced and dosimetric. Respir Care 49:174–179
Leung K, Louca E, Coates AL (2004) Comparison of breath enhanced to breath actuated nebulisers for rate, consistency and efficiency. Chest 126:1619–1627
Nerbrink OL, Pagels J, Pieron CA, Dennis JH (2003) Effect of humidity on constant output and breath enhanced nebuliser designs when tested in the EN 13544-1 EC standard. Aerosol Sci Technol 37:282–292
Moghimi SM, Szebini J (2003) Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonisation and protein binding properties. Prog Lipid Res 42:463–478
Anabousi S, Kleemann E, Bakowsky U, Kissel T, Schmehl T, Gessler T, Seeger W, Lehr CM, Ehrhardt C (2006) Effect of PEGylation on the stability of liposomes during nebulisation and in lung surfactant. J Nanosci Nanotechnol 6:3010–3016
Kleemann E, Schmehl T, Gessler T, Bakowsky U, Kissel T, Seeger W (2007) Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: Formulation aspects and stability. Pharm Res 24:277–287
Gilbert BE (1996) Liposomal aerosols in the management of pulmonary infections. J Aerosol Med 9:111–122
Pandey R, Khuller GK (2005) Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother 55:430–435
Gaspar MM, Cruz A, Fraga AG, Castro AG, Cruz ME, Pedrosa J (2008) Developments on drug delivery systems for the treatment of mycobacterial infections. Curr Top Med Chem 8:579–591
Chinmote G, Banerjee R (2008) Evaluation of antitubercular drug-loaded surfactants as inhalable drug-delivery systems for pulmonary tuberculosis. J Biomed Mater Res A 89:281–292
Conley J, Yang H, Wilson T, Blasetti K, Di Ninno V, Schnell G, Wong JP (1997) Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterisation and efficacy against Francisella tularensis infection in mice. Antimicrob Agents Chemother 41:1288–1292
Wong JP, Yang H, Blasetti KL, Schnell G, Conley J, Schofield LN (2003) Liposome delivery of ciprofloxacin against Francisella tularensis infection. J Control Release 92:265–273
Gilbert BE, Six HR, Wilson SZ, Wyde PR, Knight V (1988) Small particle aerosols of enviroxime-containing liposomes. Antivir Res 9:355–365
Wyde PR, Six HR, Wilson SZ, Gilbert BE, Knight V (1988) Activity against rhinoviruses, toxicity and delivery in aerosol of enviroxime in liposomes. Antimicrob Agents Chemother 32:890–895
Knight V, Gilbert B (1988) Antiviral therapy with small particle aerosols. Eur J Clin Microbiol Infect Dis 7:721–731
Gavalda J, Martin M, Lopez P, Gomis X, Ramirez J, Rodriguez D, Len O, Puigfel Y, Ruiz I, Pahissa A (2005) Efficacy of nebulised liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Antimicrob Agents Chemother 49:3028–3030
Gilbert BE, Wyde PR, Lopez-Berestein G, Wilson SZ (1994) Aerosolised amphotericin B-liposomes for treatment of systemic candida infections in mice. Antimicrob Agents Chemother 38:356–359
Ruijgrok EJ, Vulto AG, Van Etten EW (2000) Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats. J Pharm Pharmacol 52:619–627
Gilbert BE, Wyde PR, Wilson SZ (1992) Aerosolised liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice. Antimicrob Agents Chemother 36:1466–1471
Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, Bonner DP (1991) Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 35:615–621
Gondal JA, Swartz RP, Rahman A (1989) Therapeutic evaluation of free and liposome encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother 33:1544–1548
Ruijgrok EJ, Vulto AG, Van Etten EW (2001) Efficacy of aerosolised amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother 48:89–95
Rao RD, Markovic SN, Anderson PM (2003) Aerosol therapy for malignancy involving the lungs. Curr Cancer Drug Targets 3:239–250
Anderson PM, Katsanis E, Leonard AS, Schow D, Loeffler CM, Goldstein MB, Ochoa AC (1990) Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases. Cancer Res 50:1853–1856
Khanna C, Hasz DE, Klausner JS, Anderson PM (1996) Aerosol delivery of interleukin 2 liposomes is non-toxic and biologically effective: canine studies. Clin Cancer Res 2:721–734
Khanna C, Anderson PM, Hasz DE, Katsanis E, Neville M, Klausner JS (1997) Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 79:1409–1421
Ten RM, Anderson PM, Zein NN, Temesgen Z, Clawson ML, And Weiss W (2002) Interleukin-2 liposomes for primary immune deficiency using the aerosol route. Int Immunopharmacol 2:333–344
Wittgen BP, Kunst PW, van der Born K, Peters GJ, Perez-Soler R, Metzheiser B, Nicholson S, Perkins W, Pilkiewicz F, Postmus PE (2006) Phase I study of aerosolised SLIT cisplatin in the treatment of patients with carcinoma of the lung. J Clin Oncol 24:7131
Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V (2001) Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 7:3258–3262
Knight V, Koshkina NV, Waldrep JC, Giovanella BC, Gilbert BE (1999) Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol 44:177–186
Koshkina NV, Kleinerman ES, Waidrep C, Jia SF, Worth LL, Gilbert BE, Knight V (2000) 9-nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 6:2876–2880
Knight V, Kleinerman ES, Waldrep JC, Giovanella BC, Gilbert BE, Koshkina NV (2000) 9-nitrocamptothecin liposome treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Ann N Y Acad Sci 922:151–163
Zhang LJ, Xing B, Wu J, Xu B, Fang XL (2008) Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes. Pulm Pharmacol Ther 21:239–246
Gilbert BE, Seryshey A, Knight V, Brayton C (2002) 9-nitrocamptothecin liposome aerosol: lack of subacute toxicity in dogs. Inhal Toxicol 14:185–197
Verschraegen CF, Gilbert BE, Loyer E, Huaringa A, Walsh G, Newman RA, Knight V (2004) Clinical evaluation of the delivery and safety of aerosolised liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 10:2319–2326
Widera A, Norouziyan F, Shen WC (2003) Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv Drug Deliv Rev 55:1439–1466
Anabousi S, Bakowsky U, Schneider M, Huwer H, Lehr CM, Ehrhardt C (2006) In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur J Pharm Sci 29:367–374
Zhao M, Fernandez LG, Doctor A, Sharma AK, Zarbock A, Tribble CG, Kron IL, Laubach VE (2006) Alveolar macrophage activation is a key initiation signal for acute lung ischemia reperfusion injury. Am J Physiol Lung Cell Mol Physiol 291:L1018–L1026
Nakamura T, Abu-Dahab R, Menger MD, Schafer U, Vollmar B, Wada H, Lehr CM, Schafers HJ (2005) Depletion of alveolar macrophages by clodronate-liposomes aggravates ischemia-reperfusion injury of the lung. J Heart Lung Transplant 24:38–45
Leemans JC, Juffermans NP, Florquin S, van Rooijen N, Vervoordeldonk MJ, Verbon A, van Deventer SJ, van der Poll T (2001) Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice. J Immunol 166:4604–4611
Chono S, Tanino T, Seki T, Morimoto K (2006) Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J Drug Target 14:557–566
Chono S, Tanino T, Seki T, Morimoto K (2007) Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification. J Pharm Pharmacol 59:75–80
Lambros MP, Bourne DWA, Abbas SA, Johnson DL (1997) Disposition of aerosolised liposomal amphotericin B. J Pharm Sci 86:1066–1069
Vyas SP, Quraishi S, Gupta S, Jaganathan KS (2005) Aerosolised liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm 296:12–25
Vyas SP, Kannan ME, Jain S, Mishra V, Singh P (2004) Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 269:37–49
Chono S, Tanino T, Seki T, Morimoto K (2008) Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects. Drug Dev Ind Pharm 34(10):1090–1096
Liu FY, Shao Z, Kildsig DO, Mitra AK (1993) Pulmonary delivery of free and liposomal insulin. Pharm Res 10:228–232
Huang YY, Wang CH (2006) Pulmonary delivery of insulin by liposomal carriers. J Control Release 113:9–14
Chono S, Fukuchi R, Seki T, Morimoto K (2009) Aerosolised liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery. J Control Release 137:104–109
Karathanasis E, Bhavane R, Annapragada AV (2006) Triggered release of inhaled insulin from the agglomerated vesicles: pharmacodynamic studies in rats. J Control Release 113(2):117–127
Hajos F, Stark B, Hensler S, Prassl R, Mosgoeller W (2008) Inhalable liposomal formulation of vasoactive intestinal peptide. Int J Pharm 357:286–294
Stark B, Andreae F, Mosgoeller W, Edetsberger M, Gaubitzer E, Koehler G, Prassl R (2008) Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation. Eur J Pharm Biopharm 70(1):153–164
Rubinstein I, Ikezaki H, Onyüksel H (2006) Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters. Int J Pharm 316(1–2):144–147
Laube BL (2005) The expanding role of aerosols in systemic drug delivery, gene therapy and vaccination. Respir Care 50:1161–1176
Griesenbach U, Geddes DM, Alton EW (2006) Gene therapy progress and prospects: cystic fibrosis. Gene Ther 13:1061–1067
Schwarz LA, Johnson JL, Black M, Cheng SH, Hogan ME, Waldrep JC (1996) Delivery of DNA-cationic liposome complexes by small-particle aerosol. Hum Gene Ther 10:731–741
Li SD, Huang L (2006) Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm 3:579–588
Durcan N, Murphy C, Cryan SA (2008) Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol Pharm 5(4):559–566
Kleemann E, Dailey LA, Abdelhady HG, Gessler T, Schmehl T, Roberts CJ, Davies MC, Seeger W, Kissel T (2004) Modified polyethylenimines as non-viral gene delivery systems for aerosol gene therapy: investigations of the complex structure and stability during air-jet and ultrasonic nebulization. J Control Release 100(3):437–450
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Controlled Release Society
About this chapter
Cite this chapter
Swaminathan, J., Ehrhardt, C. (2011). Liposomes for Pulmonary Drug Delivery. In: Smyth, H., Hickey, A. (eds) Controlled Pulmonary Drug Delivery. Advances in Delivery Science and Technology. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9745-6_14
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9745-6_14
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-9744-9
Online ISBN: 978-1-4419-9745-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)